Want to see NAUT full AI Analyst Report?

Nautilus Biotechnolgy (NAUT) Price & Analysis

235 Followers

NAUT Stock Chart & Stats

$0.88

-$0.08(-4.52%)

At close: Jul 24 4:00 PM EDT

$0.88

-$0.08(-4.52%)

Day’s Range― - ―

52-Week Range$0.84 - $4.31

Previous CloseN/A

Volume624.38K

Average Volume (3M)8.25M

Market Cap

$310.50M

Enterprise Value$181.53M

Total Cash (Recent Filing)$86.58M

Total Debt (Recent Filing)$26.74M

Price to Earnings (P/E)―

Beta0.85

Next Earnings

Mar 04, 2027

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding127,255,226

10 Day Avg. Volume9,816,780

30 Day Avg. Volume8,253,907

Financial Highlights & Ratios

PEG Ratio0.26

Price to Book (P/B)1.57

Price to Sales (P/S)0.00

P/FCF Ratio-4.74

Enterprise Value/Market Cap0.58

Enterprise Value/Revenue428.13

Enterprise Value/Gross Profit-118.11

Enterprise Value/Ebitda-3.21

Forecast

1Y Price Target

$3.83

Price Target Upside335.61% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.51

Revenue Forecast (FY)$536.25K

Bulls Say, Bears Say

Bulls Say

Assay ReproducibilityLow assay variability across tau and multiple oncology targets supports confidence that Voyager’s performance can transfer beyond one use case. Repeatable data quality may strengthen adoption across research and drug-discovery workflows while enabling a broader consumables and assay portfolio.

Commercialization RoadmapA defined launch sequence gives the company a tangible path from Early Access services toward instrument placements and recurring assay consumption. Planned assay expansion and lower sample requirements could broaden the addressable customer base if execution remains on schedule.

External Validation And Partnership FundingParticipation in a substantial consortium provides external validation, funded development work, and additional applications in Alzheimer’s disease and Ewing sarcoma. The program can support platform optimization and assay development while expanding scientific and commercial relationships.

Bears Say

Minimal Revenue And Deep LossesThe very small revenue base shows that commercialization has not yet reached meaningful scale, while substantial operating losses indicate limited operating leverage. The company must continue investing heavily before its platform can support a self-funding business model.

Persistent Cash Burn And Funding NeedsSustained cash consumption requires Nautilus to preserve liquidity while funding assay development, platform expansion, and commercial hiring. Even with a stated runway into Q1 2028, additional financing may remain important to execute the roadmap and could constrain capital allocation.

Early Customer And Instrument FunnelAn early, concentrated sales funnel makes future placements and recurring consumable revenue dependent on converting a limited set of initial opportunities. Reliance on tau activity and the need to develop pharma and philanthropic projects increase execution risk during the transition to commercial scale.

Nautilus Biotechnolgy News

Nautilus Biotechnology reports Q3 EPS (12c) vs. (11c) last year

Reports Q3 revenue $200K, consensus $206.25K. Cash, cash equivalents, and investments were $114.3M as of September 30, 2026....

11h ago

NAUT

Nautilus Biotechnology initiated with a Buy at Roth Capital

Roth Capital analyst Max Masucci initiated coverage of Nautilus Biotechnology (NAUT) with a Buy rating and $3.50 price...

29d ago

NAUT

NAUT Upcoming Earnings Report: What to Expect?

Nautilus Biotechnolgy, Inc. (NAUT) is scheduled to report 3rd quarter earnings on 10/27/2026, before the market opens. Regarding...

3d ago

NAUT

Nautilus Biotechnology Establishes New At-The-Market Offering

An update from Nautilus Biotechnolgy ( ($NAUT) ) is now available. On September 11, 2026, Nautilus Biotechnology entered...

2M ago

NAUT

Nautilus Biotechnology files $300M mixed securities shelf

16:07 EDT Nautilus Biotechnology (NAUT) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

NAUT

Nautilus Biotechnology initiated with an Outperform at Leerink

Leerink initiated coverage of Nautilus Biotechnology (NAUT) with an Outperform rating and $4 price target Published first on...

2M ago

NAUT

Nautilus Biotechnology Earnings Call Balances Promise and Risk

Nautilus Biotechnolgy, Inc. (($NAUT)) has held its Q2 earnings call. Read on for the main highlights of the...

2M ago

NAUT

NAUT Upcoming Earnings Report: What to Expect?

Nautilus Biotechnolgy, Inc. (NAUT) is scheduled to report 2nd quarter earnings on 07/28/2026, before the market opens. Regarding...

3M ago

NAUT

Nautilus Biotech stockholders approve directors and governance items

An announcement from Nautilus Biotechnolgy ( ($NAUT) ) is now available. Nautilus Biotechnology, Inc. held its 2026 annual...

4M ago

NAUT

NAUT Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Nautilus Biotechnolgy, Inc. (NAUT) is scheduled to report 1st quarter earnings on 04/28/2026, before the market opens. Regarding...

6M ago

NAUT

Nautilus announces first customer of its Iterative Mapping Early Access Program

Nautilus Biotechnology (NAUT) announced Baylor College of Medicine as the first customer of Nautilus’ Iterative Mapping Early Access...

7M ago

NAUT

Nautilus Biotechnology appoints Faust as Vice President of Sales

Nautilus Biotechnology (NAUT) announced the appointment of Amber Faust as Vice President of Sales. Faust joins Nautilus following...

8M ago

NAUT

Nautilus Biotechnology price target raised to $4 from $2.50 at Guggenheim

Guggenheim raised the firm’s price target on Nautilus Biotechnology (NAUT) to $4 from $2.50 and keeps a Buy...

8M ago

NAUT

Nautilus Biotechnolgy Charts Cash-Backed Path to 2027

Nautilus Biotechnolgy, Inc. (($NAUT)) has held its Q4 earnings call. Read on for the main highlights of the...

8M ago

NAUT

NAUT FAQ

What was Nautilus Biotechnolgy’s price range in the past 12 months?

Nautilus Biotechnolgy lowest stock price was $0.84 and its highest was $4.31 in the past 12 months.

What is Nautilus Biotechnolgy’s market cap?

Nautilus Biotechnolgy’s market cap is $310.50M.

When is Nautilus Biotechnolgy’s upcoming earnings report date?

Nautilus Biotechnolgy’s upcoming earnings report date is Mar 04, 2027 which is in 128 days.

How were Nautilus Biotechnolgy’s earnings last quarter?

Nautilus Biotechnolgy released its earnings results on Oct 27, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.02.

Is Nautilus Biotechnolgy overvalued?

According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nautilus Biotechnolgy pay dividends?

Nautilus Biotechnolgy does not currently pay dividends.

What is Nautilus Biotechnolgy’s EPS estimate?

Nautilus Biotechnolgy’s EPS estimate is -0.14.

How many shares outstanding does Nautilus Biotechnolgy have?

Nautilus Biotechnolgy has 127,255,226 shares outstanding.

What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?

Nautilus Biotechnolgy reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -27.711%.

Which hedge fund is a major shareholder of Nautilus Biotechnolgy?

Currently, no hedge funds are holding shares in NAUT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Nautilus Biotechnolgy Stock Smart Score

Outperform

Fundamentals

Return on Equity

-37.58%

Trailing 12-Months

Asset Growth

-23.27%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Nautilus Biotechnolgy

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnolgy (NAUT) Earnings & Revenues

Historic Earnings Reports

NAUT Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call was predominantly positive, with strong assay reproducibility, external scientific validation, new partnerships, an expanding Early Access pipeline, and a defined 2027 commercial launch roadmap. However, Nautilus remains in an early commercial phase with low revenue, a larger net loss, quarterly cash use, uncertainty around academic funding, and an early-stage instrument sales funnel.View all NAUT earnings summaries

NAUT Stock 12 Month Forecast

Average Price Target

$3.83

▲(335.61% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.8333333333333335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.57,1.756923076923077,1.9438461538461538,2.1307692307692307,2.3176923076923077,2.5046153846153847,2.691538461538461,2.878461538461538,3.065384615384615,3.252307692307692,3.439230769230769,3.626153846153846,3.813076923076923,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.57,1.7441025641025643,1.9182051282051282,2.0923076923076924,2.2664102564102566,2.440512820512821,2.6146153846153846,2.7887179487179488,2.962820512820513,3.136923076923077,3.3110256410256413,3.4851282051282055,3.6592307692307697,{"y":3.8333333333333335,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.57,1.7184615384615385,1.866923076923077,2.0153846153846153,2.163846153846154,2.312307692307692,2.460769230769231,2.609230769230769,2.7576923076923077,2.9061538461538463,3.0546153846153845,3.2030769230769227,3.3515384615384614,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.01,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.355,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.84,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.977,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.926,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.57,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >